The United States Adalimumab Market remains one of the largest and most influential segments of the global biologics industry, driven by the increasing prevalence of autoimmune and inflammatory diseases. Adalimumab is widely prescribed across the country for the treatment of rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, hidradenitis...